Melanotan 1

Peptideprescription

Synthetic alpha-MSH analogue also known as NDP-MSH or afamelanotide. Controlled clinical research and the approved implant must not be conflated with unregulated daily-injection products sold as Melanotan I.

Pharmacokinetic model

A route-level PK model for melanotan 1 is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category
Peptide
Suggested cadence
once daily

Research behind this entry

  1. Effect of MELANOTAN, [Nle4, D-Phe7]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM · Peptides, 2006 DOI

    Placebo-controlled study in 77 white participants found increased melanin density after the studied Melanotan preparation, including among several MC1R variant groups. It does not validate grey-market product purity or…

  2. An unhealthy glow? A review of melanotan use and associated clinical outcomes Brennan R, Wells JSG, Van Hout MC · Performance Enhancement and Health, 2015 DOI

    Review catalogued reported tanning effects and adverse clinical outcomes for Melanotan I and II, while emphasizing weak reporting and unknown long-term toxicology. It cannot assign events reliably to a verified…

2 published studies referenced in the app, each with a plain-language summary.